Tag:
NGX-4010
Latest Headlines
Latest Headlines
NeurogesX reports positive Phase III data
NeurogesX is touting positive data from the second late-stage study of NGX-4010, a dermal patch therapy for patients with postherpetic neuralgia. The study hit its primary endpoint with a 32 percent
